UNDERSTANDING MYELOMA Brian G.M. Durie, M.D. Chairman International Myeloma Foundation.

Slides:



Advertisements
Similar presentations
How to Manage High Risk Myeloma Dr Matthew Jenner Consultant Haematologist Southampton General Hospital UK Myeloma Forum Autumn Day 12 November 2014.
Advertisements

Staff Oncologist, Mayo Clinic Arizona
Childhood Acute Lymphoblastic Leukemia Kelsey Shaffer CHTN Staff Meeting Presentation.
FAITH OLUWATOSIN ILORI INTRODUCTION PATHOPHYSIOLOGY CAUSES STAGES SIGNS AND SYMPTOMS DIAGNOSIS RISK FACTORS TREATMENT COMPLICATIONS PROGNOSIS EPIDEMILOGY.
CLL- Chronic Lymphocytic Leukemia
Objectives To introduce the terminology used in describing the plasma cells neoplasm. To explain the physiology of the normal cells & the pathological.
Acute Leukaemia Dr. Soheir Adam, MRCPath Assistant Professor Department of Haematology, KAUH.
OncoTracker James Berenson, MD President and CEO November 2014.
Chronic lymphocytic leukemia (1)
Chronic Lymphocytic Leukemia. Definition Clonal B cell malignancy. Progressive accumulation of long lived mature lymphocytes. Increase in anti-apoptotic.
Waleed Awwad, MD, FRCSC. Red Flags: Red Flags: History of cancer History of cancer Unexplained weight loss >10 kg within 6 months Unexplained weight.
Breast Cancer By George Rezk.
CANCER. THE WORD CANCER  FEAR  DEATH  PAIN  SUFFERING  LOSS  ECONOMIC LOSS  DISFIGUREMENT  WHAT’S THE FUTURE.
GASTRIC LYMPHOMAS Aswad H. Al.Obeidy FICMS, FICMS GE&Hep Kirkuk General Hospital.
Thalidomide, Radiation, and Peripheral Stem Cell Transplantation as Combination Treatment for Multiple Myeloma Allison Reczek Department of Biological.
NYU Medical Grand Rounds Clinical Vignette Ankit Parikh MD, PGY-2 January 6, 2009 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.
Leukemia & Lymphoma Keith Rischer, RN, MA, CEN. Leukemia Patho Loss of regulation in cell division, causes proliferation of malignant leukocytes Classification.
Hodgkin’s Lymphoma By: Tonya Weir and Paige Mathias Date: October 13, 2010.
Cancer Among Native Americans in Arizona and New Mexico Data Provided by Arizona Cancer Registry at the Arizona Department of Health Services and the New.
Multiple Myeloma Definition:
Multiple Myeloma Presented by: Mike Lynch Mike Lynch.
Multiple Myeloma Definition: B-cell malignancy characterised by abnormal proliferation of plasma cells able to produce a monoclonal immunoglobulin (M protein)
Plasma cell Disorders S. Sami Kartı, MD, Prof.. Plasma cells  Terminally differentiated cells of B- lymphocyte lineage  Produce antibodies  Normal.
Multiple Myeloma Definition:
Plasma Cell Disorders Kristi McIntyre M.D. Texas Oncology 2004 Monoclonal Gammopathies.
Awareness Is Everything By Karis M. Blalock. Hypothesis Why is it important to understand what Multiple Myeloma is?
Clinical Division of Oncology Department of Medicine I Medical University of Vienna, Austria MULTIPLE MYELOMA.
Epidemiology 12,000 deaths in United States per year
CASE 5 56 yr-old man HIV Asymptomatic CD4 840 HIV viral load
Core Benefit/Risk (CR)
Treatment Multiple Myeloma. Symptomatic/progressive myeloma: Systemic therapy - to control progression of myeloma Supportive care - to prevent serious.
Multiple Myeloma Morning Report July 21, 2009 Lindsay Kruska.
Justin A. Crocker.  1 of the monoclonal gammopathies  Neoplastic proliferation of immunoglobulin producing plasma cells (single clone), often resulting.
APPROACH TO LYMPHOID MALIGNANCIES. Patient Evaluation of ALL Careful history and PE CBC Chemistry studies Bone marrow biopsy Lumbar puncture.
Plasma cell dyscrasias. Multiple Myeloma By Dr. Muna A. Kashmool.
Jesse C James MD AM Report May 7,  Proliferation of malignant plasma cells and a subsequent overabundance of monoclonal paraprotein  Malignant.
Osteonecrosis of the Jaws in Myeloma BRIAN G.M. DURIE, M.D., Michael Katz, Jason McCoy, MS and John Crowley, PhD Hematology/Oncology, Cedars-Sinai Outpatient.
Robert Z. Orlowski, MD, PhD Associate Professor of Lymphoma/Myeloma and of Experimental Therapeutics Division of Cancer Medicine Director, Myeloma Section.
LYMPHOMA & MULTIPLE MYELOMA Arleigh McCurdy MD FRCPC.
IMAJEM, a Substudy of IFM 2009: Prognostic Role of MRI and PET/CT in MM New Findings in Hematology: Independent Conference Coverage* of ASH 2015, December.
Multiple Myeloma March 13, 2012 Suzanne R. Fanning, DO Greenville Health System.
Challenging cases: Which imaging technique to use and to incorporate into clinical practice Consultant Haematologist University College London Hospital.
Leukemia. What is Leukemia?  Leukemia is a cancer of the blood  It is the most common type of blood cancer beginning in the bone marrow where abnormal.
R4 Jae Joon Han.
Hematopoietic Stem Cell Transplantation (HSCT)
Non-Hodgkin Lymphoma March 13, 2013 Suzanne R. Fanning, DO Greenville Health System.
Multiple Myeloma: Is it now a curable disease?
Childhood Hodgkin Lymphoma Cases and Controversies Eurasian Commonwealth Online Conference 5/25/05 Scott Howard, MD, MSc St. Jude Children’s Research Hospital.
Long-term outcome results of the first tandem autotransplant trial for multiple myeloma Bart Barlogie, Guido J. Tricot, Frits van Rhee, Edguardo Angtuaco,
Case Study Multiple Myeloma.
Multiple Myeloma in Session 2015: An Online Journal Club for Hematology/Oncology Fellows This program is supported by educational grants from Celgene Corporation.
Prepared by : IBRAHEEM NIDAL ABU ATWAN SAEED YEHYA HAMMODA
Myeloma hope new treatment in the horizon
Session 7, case 171 Extramedullary Manifestations of Myeloid Neoplasms
Korde N et al. Proc ASH 2012;Abstract 732.
IFM/DFCI 2009 Trial: Autologous Stem Cell Transplantation (ASCT) for Multiple Myeloma (MM) in the Era of New Drugs Phase III study of lenalidomide/bortezomib/dexamethasone.
Phase III EMN02/HO95 MM Trial: Upfront ASCT Prolongs PFS vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed MM CCO Independent Conference Coverage*
Dr WAQAR ASST. PROFESSOR INTERNAL MEDICINE
Diagnosis of Solitary Plasmocytoma
Yale University School of Medicine
How I treat extramedullary myeloma
Comorbidity NASH/HCV and HCC
Challenging Cases in Multiple Myeloma Panel Discussion
A young patient with multiple myeloma
Clinical Challenges in the Transplant-Eligible Patient With Newly Diagnosed Multiple Myeloma.
Leukemia.
Whole-Body Imaging in Multiple Myeloma
CANCER Detection and Treatment
Clinical Challenges in the Transplant-Eligible Patient With Newly Diagnosed Multiple Myeloma.
Maintenance therapies in Multiple Myeloma
Presentation transcript:

UNDERSTANDING MYELOMA Brian G.M. Durie, M.D. Chairman International Myeloma Foundation

Most Common Initial Problems Bone pain Bone pain Anemia/Fatigue Anemia/Fatigue NO Problems: Incidental finding during routine exam NO Problems: Incidental finding during routine exam Kidney problem Kidney problem Other Other

Diagnosis Bone Marrow Imaging Electro- pheresis

Bone Lesions In Myeloma Lytic lesions LEGELBOW

Staging Single lesion Single lesion  Solitary plasmacytoma  Stage I Multiple lesions Multiple lesions  Stages II / III A/B A – Creatinine < 2mg /DL B – Creatinine > 2mg/DL

SOLITARY PLASMACYTOMA T1-wt MRISTIR – wt MRI Sagittal CT Sagittal FDG PET

STAGING WITH FDG PET FL on PET & MRI: Multiple Myeloma FDG PET: Severe Diffuse (D) and Focal (F) DiseaseD D D D D F F F F D MRI – STIR weighted of thoracic spine FDG PET scan of thoracic spine

Pretreatment 3 months later Confirmation of Remission Plasmacytomas

MYELOMA PROTEIN “SPIKE” Low AlbuminSpike

International Staging System  2 M / S. Alb Stage 1 Low  2 M < 3.5* plus S. Albumin** > 3.5 G/DL Stage 2  2 M < 3.5 but albumin < 3.5 Or  2 M or higher: 3.5 – < 5.5 Stage 3 High  2 M > 5.5mg/DL * mg/DL ** Gm/DL

Other Factors Impact of AGE Impact of AGE C-Reactive Protein (CRP) C-Reactive Protein (CRP) LDH LDH Chromosome 13 Chromosome 13  Cytogenetic deletion  FISH analysis Micro array classification Micro array classification

Genetic Studies in Myeloma Gene Array: Normal vs MM MM +/- Bone Disease Sky Karyotype No Lytic Lesions> 3 Lytic Lesions Normal Bone Marrow Cells Clonally restricted PC w/o Chromosome 13 deletion Clonally restricted PC w / Chr. 13 deletion D13S31 D10S2142 anti-kappa NPCMM High Gene Expression Low 120 genes NL Myeloma CA13 – Tri-FISH DKK1, FRZB, CENPA, TYMS, TTK, MAD2L1, PCNA, PRKDC, CCNF, AML1B WNT10B, ARHE, LNHR, SLAM, TACI, PIM1, IL6R, BIK, BAX, CFLAR

Starting Treatment Supportive Measures – for pain, anemia, infection … Supportive Measures – for pain, anemia, infection … Systemic Therapy – oral and/or I.V. treatment Systemic Therapy – oral and/or I.V. treatment

Supportive Care Bone – Aredia or Zometa Bone – Aredia or Zometa Anemia – EPOProcrit/Epogen Anemia – EPOProcrit/Epogen Other – radiation, antibiotics, fluids, pain, medication … Other – radiation, antibiotics, fluids, pain, medication …

First Therapy Induction or Frontline Saving Stem Cells Saving Stem Cells  VAD  DEX  Thalidomide/Dexamethasone  Cytoxan NOT Saving Stem Cells NOT Saving Stem Cells  M/P  Other combos

Next Steps Harvesting Harvesting “Consolidation” “Consolidation”  Auto stem cell transplant  “Mini-allo” Maintenance Maintenance

Clear Recommendation Required

Mutual Agreement is Essential

MENTAL HEALTH Stress reduction Stress reduction Confidence in treatment plan Confidence in treatment plan Expectation of remission Expectation of remission Future plans Future plans HOPE HOPE

YOUR DOCTOR Informed Informed Cooperative Cooperative Open to discussing options Open to discussing options Caring for YOU Caring for YOU

Caring and Trust are Crucial

Help Others When You Can